TY  - JOUR
AU  - Vivancos, Ana
AU  - Aranda, Enrique
AU  - Benavides, Manuel
AU  - Elez, Elena
AU  - Gomez-España, Maria Auxiliadora
AU  - Toledano, Marta
AU  - Alvarez, Martina
AU  - Parrado, Maria Rosario Chica
AU  - Garcia-Barberan, Vanesa
AU  - Diaz-Rubio, Eduardo
PY  - 2019
DO  - 10.1038/s41598-019-45616-y
UR  - http://hdl.handle.net/10668/14152
T2  - Scientific reports
AB  - KRAS mutations are common in colorectal cancer (CRC). In this setting, mutation status determination in circulating-free DNA from blood samples (liquid biopsy) has been shown to be a viable alternative to tissue testing. The objective of this study...
LA  - en
PB  - Nature Publishing Group
KW  - Middle Aged
KW  - Mutation
KW  - Prognosis
KW  - Proto-Oncogene Proteins p21(ras)
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Biomarkers, Tumor
KW  - Cell-Free Nucleic Acids
KW  - Colorectal Neoplasms
KW  - DNA Mutational Analysis
KW  - Early Detection of Cancer
KW  - Female
KW  - Humans
KW  - Liquid Biopsy
KW  - Male
TI  - Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples.
TY  - research article
VL  - 9
ER  -